A multicenter, open-label sub-study to LMF237A2302 to assess the effect of 24 weeks treatment with initial combination of vildagliptin 100mg qd [once daily] plus metformin 1000mg Bid [twice daily] in drug naive patients with type 2 diabetes with very poor glycemic control
Phase of Trial: Phase III
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Metformin; Vildagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 21 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 May 2009 Results published in Diabetes, Obesity and Metabolism.